February 27, 2017 / 5:23 PM / in 8 months

BUZZ-Valeant Pharma: Bolsters Salix sales force

** Canadian drugmaker’s U.S.-listed shares up 3 pct at $16.68; Toronto-listed shares also up about 3 pct

** Scales up gastrointestinal unit Salix’s sales force by nearly 40 pct

** To report Q4 results before the bell Tuesday; Q4 adj. EPS expected to drop 51.4 pct to $1.21, per TR I/B/E/S

** Mizuho analysts lower PT to $9 from $11, citing concerns about eroding asset base and lack of organic growth ahead of 2017 guidance; median PT is $20

** Valeant may, however, beat 4Q:16 expectations - Mizuho

**Including the 2.97 percent gain in the session at 12:15PM, shares of Valeant Pharma were up 14.74 percent YTD; stock plunged 60 pct in 2016

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below